The MHRA has issued repeated safety alerts about the risks of purchasing unlicensed injectable peptides including GLP-1 receptor agonists and weight-loss injections from unregulated online sources, citing concerns about: Uncertain purity and potency of preparations not manufactured under GMP conditions Absence of validated stability data , including reconstituted shelf life and beyond-use dates Risk of microbial contamination in preparations made outside licensed aseptic facilities Mislabelling, adulteration, or counterfeit products sold through unregulated channels NICE guidance on pharmacotherapy for obesity currently covers licensed agents only
The warning reads: The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient of OZEMPIC
But in the Retatrutide Phase 2 Obesity trial, Low Wang said that 100% of study volunteers who received 8 milligrams or more of the medication rather than the placebo lost at least 5% of their body weight
However, it is essential to follow the specific instructions provided by your healthcare provider, as they will take into consideration your unique medical history and overall health
These antihyperglycemic agents stimulate insulin secretion and inhibit the release of glucagon from pancreatic islets in a glucose-dependent manner
The side effects after the first couple months